TrovaGene Inc. (Nasdaq: TROV) entered an agreement to offer its (ct)DNA Precision Cancer Monitoring tests and and services to America's Choice Provider Network patients. The stock price soared $1.13 to $4.48.
TrovaGene enters agreement with America's Choice Provider Network
January 21, 2016 at 10:56 AM EST
